Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs

American Journal of Veterinary Research

Volumn 62, Issue 4, 2001, Pages 595-598

  Mischke, Reinhard ^a   Grebe, Susanne ^a   Jacobs, Christina ^a   Kietzmann, Manfred ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG ACTIVITY; FEMALE; HEMATOCRIT; HEMOSTASIS; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; SCREENING TEST; THROMBIN TIME; THROMBOCYTE COUNT;

ANIMALIA; CANIS FAMILIARIS;

EID: 0035076822     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.595     Document Type: Article

References (24)

1. Fareed J, Jeske W, Eschenfelder V, et al. Preclinical studies on a low molecular weight heparin. Thromb Res 1996;81(suppl2): 1-27.
2. Brindley CJ, Taylor T, Diness V, et al. Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. Xenobiotica 1993;23: 575-588.
3. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(suppl 5):489-510.
4. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits Blood 1982;59:1239-1245.
5. Henny CP, ten Cate H, ten Cate JW, et al. A randomized blind study comparing standard heparin and a new molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J Lab Clin Med 1985;106:187-196.
6. Mestre M, Clairefond P, Mardiquinan J, et al. Comparative effects of heparin and PK 10169, a low molecular weight fraction, in a canine model of arterial thrombosis. Thromb Res 1985;38:389-399.
7. Jun L, Arnout J, Vanhove P, et al. Comparison of a low molecular weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Coron Artery Dis 1995;6:257-263.
8. Leadley RJ, Kasiewski CJ, Bostwick JS, et al. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol 1998;18:908-914.
9. Grebe S, Jacobs C, Kietzmann M, et al. Pharamkokinetik des niedermolekularen heparins Fragmin D beim hund. Berl Muench Tieraerztl Wochenschr 2000;113:103-107.
10. Harenberg J, Huhle G, Piazolo L, et al. Niedermolekulare heparine. Prophylaxe und therapie thromboembolischer erkrankungen. Hautarzt 1997;48:852-864.
11. Nieuwenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2237-2343.
12. Alhenc-Gelas M, Le Guernic JC, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71: 698-702.
13. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-374.
14. Harenberg J, Giese Ch, Dempfle CE, et al. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989;61:357-362.
15. Bratt G, Toernebohm E, Wilund L, et al. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42:613-620.
16. Bergquvist D, Hedner U, Sjörn E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983;32:381-391.
17. Matthias FR, Ditter H. Prophylaxe und therapie tiefer venenthrombosen mit heparin - speziell in der chirurgie frischer venenthrombosen. Folia Angiol 1984;32:5-8.
18. Holmer E. Anticoagulant properties of heparin and heparin fractions. Scand J Haematol 1980;25(suppl 36):25-39.
19. Hansen JB, Sandset PM. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Thromb Res 1998;91:177-181.
20. Hellebrekers LJ, Slappendel RJ, van den Brom WE. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res 1985;46: 1460-1463.
21. Greinacher A. Heparin-induzierte thrombozytopenien. Internist Berl 1996;37:1172-1178.
22. Mahaffey EA, Moore JN. Erythrocyte agglutination associated with heparin treatment in three horses. J Am Vet Med Assoc 1986; 11:1478-1480.
23. Monreal L, Villatoro AJ, Monreal M, et al. Comparison of the effects of low-molecular-weight and unfractionated heparin in horses. Am J Vet Res 1995;56:1281-1285.
24. Samama MM, Bara L, Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 1996;52(suppl 7):8-14.